A quiet revolution in global public health: The World Health Organization's Prequalification of Medicines Programme

被引:54
|
作者
't Hoen, Ellen F. M. [1 ]
Hogerzeil, Hans V. [2 ]
Quick, Jonathan D. [3 ]
Sillo, Hiiti B. [4 ]
机构
[1] Med Law & Policy, F-75011 Paris, France
[2] Univ Groningen, NL-9713 AV Groningen, Netherlands
[3] Management Sci Hlth, Cambridge, MA 02139 USA
[4] TFDA, Dar Es Salaam, Tanzania
关键词
medicines quality; HIV; WHO Prequalification of medicines programme; access to medicines; patents; FIXED-DOSE COMBINATION;
D O I
10.1057/jphp.2013.53
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Problems with the quality of medicines abound in countries where regulatory and legal oversight are weak, where medicines are unaffordable to most, and where the official supply often fails to reach patients. Quality is important to ensure effective treatment, to maintain patient and health-care worker confidence in treatment, and to prevent the development of resistance. In 2001, the WHO established the Prequalification of Medicines Programme in response to the need to select good-quality medicines for UN procurement. Member States of the WHO had requested its assistance in assessing the quality of low-cost generic medicines that were becoming increasingly available especially in treatments for HIV/AIDS. From a public health perspective, WHO PQP's greatest achievement is improved quality of life-saving medicines used today by millions of people in developing countries. Prequalification has made it possible to believe that everyone in the world will have access to safe, effective, and affordable medicines. Yet despite its track record and recognized importance to health, funding for the programme remains uncertain.
引用
收藏
页码:137 / 161
页数:25
相关论文
共 50 条